Armata Pharmaceuticals (ARMP) Non-Current Debt (2023 - 2026)

Armata Pharmaceuticals has disclosed Non-Current Debt across 4 years of filings, most recently posting $88.0 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $88.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $88.0 million (changed N/A YoY), and the FY2025 annual result was $103.1 million, up 357.26% from the prior year.
• Non-Current Debt came in at $88.0 million for Q1 2026 at Armata Pharmaceuticals, down from $103.1 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $103.1 million in Q4 2025 to a low of $15.2 million in Q3 2025.
• The 4-year median for Non-Current Debt is $23.7 million (2023), against an average of $44.3 million.
• Across the five-year window, Non-Current Debt slipped 4.79% in 2024 and surged 357.26% in 2025, its largest moves.
• Armata Pharmaceuticals' Non-Current Debt stood at $23.7 million in 2023, then declined by 4.79% to $22.5 million in 2024, then soared by 357.26% to $103.1 million in 2025, then slipped by 14.64% to $88.0 million in 2026.
• The last three Non-Current Debt figures came in at $88.0 million (Q1 2026), $103.1 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.